Franklin K. Clyburn
Independent Non-Employee DirectorMr. Franklin K. Clyburn, Jr. also known as Frank, is Independent Director of Cencora, Inc. from October 1, 2024. He serves as Non-Executive Board Member since May 2026 at Real Chemistry, Inc. He serves as an Independent Non-Employee Director at Kailera Therapeutics, Inc. since October 2025. He is Independent Director of Revolution Medicines, Inc. from August 5, 2024. He had been the Chief Executive Officer and Director of International Flavors & Fragrances Inc. since February 14, 2022 until February 6, 2024 and remained with IFF until March 31, 2024. He served as President of Nourish Division at nternational Flavors & Fragrances Inc. since December 31, 2022. He served as President of Human Health at Merck & Co. Inc. since March 17, 2021 until February 01, 2022 and served as its Executive Vice President since March 2021 until February 01, 2022. He had been the Chief Commercial Officer of Human Health and Executive Vice President of Merck & Co. Inc. since January 01, 2019 until March 17, 2021. Mr. Clyburn who joined the Merck & Co. Inc in 2008 and was served as President of Mercks Global Oncology Business since October 2013 until December 2018. He had been Independent Director of DuPont de Nemours, Inc. (formerly known as DowDuPont Inc.), since June 1, 2019 until January 20, 2022. Earlier in his career, Mr. Clyburn served in a wide range of commercial roles of increasing responsibility at Hoechst Marion Roussel Inc. (now part of Sanofi) from 1994 to 2000. From 2013 to 2018, he was the inaugural President of the company's Global Oncology business. Previously, he was the President of the Primary Care and Womens Health businesses and market access function. Mr. Clyburn joined the company in 2008 to lead its Biologics business. Mr. Clyburn served as Vice President & Head of U.S. Internal Medicine and Oncology Business at Sanofi Aventis, a pharmaceutical company and held various management positions of increasing responsibility within company from 1994 to 2008. Mr. Clyburn serves as a Member of the Executive Leadership Council and is on the Board of Trustees of Thomas Edison State University. He served on the Board of Directors of DuPont from June 1, 2019 to January 20, 2022, giving him familiarity with the merger between IFF and N&B to advance the integration. He serves on the Board of Directors for the European Federation of Pharmaceutical Industries and Associations (EFPIA). Mr. Clyburn received his Master of Business Administration degree from Arizona State University and his Bachelor of Arts degree from Franklin & Marshall College.
Positions
- Company NameKailera Therapeutics, Inc.Stock CodeKLRAPositionIndependent Non-Employee DirectorColleagues
- RCRonald C. RenaudPresident, CEO & Director
- JFJohn F. MilliganIndependent Non-Employee Chairman
- PDPaul Douglas BurgessChief Operating & Business Officer
- JBJamie Beth ColemanChief Commercial Officer
- DWDouglas W. PaganChief Financial Officer
- MGMaura GavaghanVice President of Corporate Communications & Investor Relations
- ATAndrew T. KaplanIndependent Non-Employee Director
- CHChristopher HiteIndependent Non-Employee Director
